Evoke Pharma, Inc.Evoke Pharma, Inc.Evoke Pharma, Inc.

Evoke Pharma, Inc.

No trades
Buy EVOK
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪5.28 M‬USD
−16.23USD
‪−7.79 M‬USD
‪5.18 M‬USD
‪751.13 K‬
Beta (1Y)
1.32
Employees (FY)
4
Change (1Y)
0
Revenue / Employee (1Y)
‪1.30 M‬USD
Net income / Employee (1Y)
‪−1.95 M‬USD

About Evoke Pharma, Inc.


CEO
Matthew J. D'Onofrio
Headquarters
Solana Beach
Founded
2007
FIGI
BBG0026ZG0X7
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of EVOK is 5.85 USD — it has decreased by −8.06% in the past 24 hours. Watch Evoke Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Evoke Pharma, Inc. stocks are traded under the ticker EVOK.
EVOK stock has risen by 15.15% compared to the previous week, the month change is a 21.02% rise, over the last year Evoke Pharma, Inc. has showed a −57.48% decrease.
We've gathered analysts' opinions on Evoke Pharma, Inc. future price: according to them, EVOK price has a max estimate of 18.00 USD and a min estimate of 18.00 USD. Watch EVOK chart and read a more detailed Evoke Pharma, Inc. stock forecast: see what analysts think of Evoke Pharma, Inc. and suggest that you do with its stocks.
EVOK reached its all-time high on Oct 7, 2013 with the price of 2,052.82 USD, and its all-time low was 3.54 USD and was reached on Sep 5, 2024. View more price dynamics on EVOK chart.
See other stocks reaching their highest and lowest prices.
EVOK stock is 16.25% volatile and has beta coefficient of 1.32. Track Evoke Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Evoke Pharma, Inc. there?
Today Evoke Pharma, Inc. has the market capitalization of ‪5.28 M‬, it has increased by 25.73% over the last week.
Yes, you can track Evoke Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Evoke Pharma, Inc. is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
EVOK earnings for the last quarter are −0.93 USD per share, whereas the estimation was −0.72 USD resulting in a −29.17% surprise. The estimated earnings for the next quarter are −0.38 USD per share. See more details about Evoke Pharma, Inc. earnings.
Evoke Pharma, Inc. revenue for the last quarter amounts to ‪2.55 M‬ USD, despite the estimated figure of ‪2.98 M‬ USD. In the next quarter, revenue is expected to reach ‪3.36 M‬ USD.
EVOK net income for the last quarter is ‪−1.27 M‬ USD, while the quarter before that showed ‪−1.58 M‬ USD of net income which accounts for 19.79% change. Track more Evoke Pharma, Inc. financial stats to get the full picture.
No, EVOK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 31, 2024, the company has 4.00 employees. See our rating of the largest employees — is Evoke Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Evoke Pharma, Inc. EBITDA is ‪−6.22 M‬ USD, and current EBITDA margin is −143.44%. See more stats in Evoke Pharma, Inc. financial statements.
Like other stocks, EVOK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Evoke Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Evoke Pharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Evoke Pharma, Inc. stock shows the sell signal. See more of Evoke Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.